We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01005485
Previous Study | Return to List | Next Study

Molecular and Morphologic Characterization of Circulating Endothelial Cells (CEC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01005485
Recruitment Status : Active, not recruiting
First Posted : November 1, 2009
Last Update Posted : March 17, 2021
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute

Brief Summary:
The primary hypothesis of this study is that circulating endothelial cells (CECs) harbor key genetic and structural characteristics predisposing individuals to acute atherosclerotic plaque rupture and heart attack.

Condition or disease
Acute Myocardial Infarction

Detailed Description:
Endothelial injury and inflammation are pivotal underlying processes that put patients at risk for catastrophic vascular events including acute myocardial infarction (heart attack) and stroke. We seek to accelerate scientific discovery through clinically meaningful, innovative translational research, and are collaborating in a trans-disciplinary effort to define the DNA sequence of CECs and that of germ line DNA, along with RNA sequencing, mRNA expression profiling, and ultrastructural characterization of CECs in order to better understand the mechanisms leading to acute arterial plaque rupture and embolization of arterial endothelial cells in patients with acute myocardial infarction. This will enable us to create a molecular fingerprint that could identify and preempt individuals from suffering from such debilitating vascular conditions.

Layout table for study information
Study Type : Observational
Actual Enrollment : 664 participants
Observational Model: Cohort
Time Perspective: Other
Official Title: Comprehensive Molecular and Morphologic Characterization of Circulating Endothelial Cells
Study Start Date : January 2010
Actual Primary Completion Date : April 2017
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Group A
Patients undergoing open vascular surgery on arterial structures to better define optimal laboratory and collection techniques for isolation of CECs.
Group B
Healthy controls will be recruited from the general medical population, community.
Acute Myocardial Infarction
Patients with acute myocardial infarction with or without ST segment deviation.

Primary Outcome Measures :
  1. The primary endpoint is complete molecular profiling of CEC's in up to 250 patients with a diagnosis of acute myocardial infarction (MI) and up to 25 healthy controls. [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA

Blood for each patient will be collected from arterial access established as part of standard of care or via venipuncture. Blood must be collected in the order listed below. By drawing the PAX gene tube first, the likelihood of contamination of the sample with vessel wall endothelial cells is decreased.


  1. x 8.5 ml PAX gene (blue top) tube
  2. x 10 ml EDTA purple top tubes

Follow-up visits: (healthy controls only)

  1. x 5 ml red top (discard)
  2. x 10 ml EDTA purple top tube

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects will be recruited from the general in-patient and out-patient populations for myocardial infarction and/or vascular surgery. Healthy controls will be recruited from the general medical population and community.

Inclusion Criteria:

  1. Age 18 - 80 years old.
  2. Must be reliable, cooperative and willing to comply with all protocol-specified procedures if consented.
  3. Able to understand and grant informed consent
  4. Subjects must meet one of the following (a-c):

    1. Healthy control subjects not meeting any exclusion criteria for controls below
    2. Patients scheduled for an open vascular procedure of an arterial structure
    3. Patients with acute MI defined as:

    i. Clinical history and symptoms consistent with acute MI AND ii Elevated cardiac markers (CKMB, Troponin I or T) consistent with MI (abnormals are according to enrolling institution's lab standards) AND iii. Able to complete study enrollment (consent & blood draw) within 48 hours of presentation to the study site.

Exclusion Criteria:

General Exclusion Criteria:

1. Has a significant medical condition that in the investigator's opinion may interfere with the patient's optimal participation in the study.

Exclusion for Healthy Controls:

  1. Age greater than 35
  2. Previous history of coronary artery disease or MI
  3. Diabetes
  4. Peripheral arterial disease
  5. Hypertension (>140/90 or on blood pressure medication)
  6. Sickle cell disease
  7. Acute or Chronic kidney disease
  8. Acute or Chronic vascular conditions, not otherwise specified
  9. Active or history of inflammation of connective tissue and vascular structures (i.e. vasculitis, rheumatoid arthritis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01005485

Layout table for location information
United States, California
La Jolla, California, United States, 92037
Sponsors and Collaborators
Scripps Translational Science Institute
Layout table for investigator information
Principal Investigator: Eric Topol, M.D. Scripps Translational Science Institute
Layout table for additonal information
Responsible Party: Eric Topol, MD, Director, Scripps Translational Science Institute, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01005485    
Other Study ID Numbers: IRB#09-5287
First Posted: November 1, 2009    Key Record Dates
Last Update Posted: March 17, 2021
Last Verified: March 2021
Keywords provided by Eric Topol, MD, Scripps Translational Science Institute:
Myocardial Infarction (MI)
Circulating Endothelial Cells (CEC)
Control Group A: (Vascular Surgery)
Control Group B: (Healthy controls)
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases